Anavex Life Sciences (AVXL) Long-Term Debt Issuances (2010 - 2014)
Anavex Life Sciences recorded quarterly Long-Term Debt Issuances of $10.0 million in Q1 2014, up 3116.59% quarter-over-quarter from -$331500.0 in Q3 2012.
Anavex Life Sciences' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $10.0 million for Q1 2014.
- In Q1 2014, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the TTM figure through Jun 2015 stood at $10.0 million (changed 0.0% YoY), while the FY2014 annual figure was $10.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances came in at $10.0 million for Q1 2014 at Anavex Life Sciences, up from -$331500.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $10.0 million in Q1 2014 to a low of -$1.4 million in Q3 2010.
- A 3-year average of $1.7 million and a median of $81500.0 in 2012 frame the typical range for Long-Term Debt Issuances.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 10.00 Mn |
| Mar 31, 2014 | 10.00 Mn |
| Sep 30, 2012 | -331,500.00 |
| Sep 30, 2012 | -331,500.00 |
| Jun 30, 2012 | 81,500.00 |
| Jun 30, 2012 | 81,500.00 |
| Mar 31, 2012 | 250,000.00 |
| Mar 31, 2012 | 250,000.00 |
| Sep 30, 2010 | -1.38 Mn |
| Sep 30, 2010 | -1.38 Mn |